2023 Annual Report

VOLUNTARY ANNOUNCEMENT PRIMARY ENDPOINTS ACHIEVED IN THE PHASE III CLINICAL TRIAL OF OT-502 IN CHINA

VOLUNTARY ANNOUNCEMENT COMPLETION OF THE PHASE III CLINICAL TRIAL OF OT-702 IN CHINA

Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 March 2024

(I) PROPOSED AMENDMENTS TO THE 2021 SHARE OPTION SCHEME; AND (II) PROPOSED AMENDMENTS TO THE 2021 SHARE AWARD SCHEME

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023

VOLUNTARY ANNOUNCEMENT PRIMARY ENDPOINTS ACHIEVED IN THE PHASE II CLINICAL TRIAL OF OT-202

DATE OF BOARD MEETING

Monthly Return of Equity Issuer on Movements in Securities for the Month ended 29 February 2024

Notification Letter to Registered Shareholders and Reply Form - Arrangement of Electronic Dissemination of Corporate Communications

Notification Letter to Non-registered Shareholders and Reply Form - Arrangement of Electronic Dissemination of Corporate Communications

Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 January 2024

Next Day Disclosure Return

Next Day Disclosure Return

Next Day Disclosure Return

DISCLOSEABLE TRANSACTION DISPOSAL OF SHARES IN EYEPOINT PHARMACEUTICALS, INC.

Next Day Disclosure Return

Next Day Disclosure Return

Next Day Disclosure Return

Next Day Disclosure Return (Resubmission)

Next Day Disclosure Return (Resubmission)

Next Day Disclosure Return

Next Day Disclosure Return

Next Day Disclosure Return

Next Day Disclosure Return

Next Day Disclosure Return

Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 December 2023

Next Day Disclosure Return

Next Day Disclosure Return